Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial

AIM: To test our hypothesis that initiating therapy with a combination of agents known to improve insulin secretion and insulin sensitivity in subjects with new-onset diabetes would produce greater, more durable reduction in glycated haemoglobin (HbA1c) levels, while avoiding hypoglycaemia and weigh...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Diabetes Obes Metab
Päätekijät: Abdul-Ghani, M. A., Puckett, C., Triplitt, C., Maggs, D., Adams, J., Cersosimo, E., DeFronzo, R. A
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2015
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5577982/
https://ncbi.nlm.nih.gov/pubmed/25425451
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12417
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia